Magaldrate and Simethicone Oral Suspension

This is a preview of
USP-NF/PF content.

Subscriber?
Access here! Not a subscriber?
Learn more!

BRIEFING

Magaldrate and Simethicone Oral Suspension. This proposal is based on the version of the monograph official as of May 1, 2022. It is proposed to omit this monograph for the following reasons:

No drug products formulated as defined under Magaldrate and Simethicone Oral Suspension are currently marketed in the United States.
The drug product is currently not on the list for approved veterinary medicine in the United States.

(SM3: J. Mcfarland)

Correspondence Number—C325535

USP REFERENCE STANDARDS FOR PURCHASE

USP Polydimethylsiloxane RS
USP Magaldrate RS

This is a preview of
USP-NF/PF content.

Subscriber?
Access here!Not a subscriber?
Learn more!